Back to search
FDAFDA · Food and drugs·Recall number D-0822-2018

Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-902-20

Published May 30, 2018 · Recall initiated: May 1, 2018

Summary

FDA records drug Class II recall D-0822-2018, published May 30, 2018 and initiated May 1, 2018. Recalling firm: Mylan Institutional, Inc. (d.b.a. UDL Laboratories); Status: Terminated; Reported quantity: 1,065 blister cards of 100 capsules each; Lot: Lot #: 3090454, Exp. 03/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Distributor
Nationwide in the U.S.
Lot
Lot #: 3090454, Exp. 03/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-902-20 recalled?

Yes. FDA published recall D-0822-2018 on May 30, 2018. Reported hazard: GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination

What should I do if I have this product?

Voluntary: Firm initiated · Letter